

Amitava Banerjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1792636/publications.pdf>

Version: 2024-02-01

199
papers

64,543
citations

32410

55
h-index

3782

185
g-index

231
all docs

231
docs citations

231
times ranked

107632
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. <i>Journal of Public Health</i> , 2023, 45, e65-e74.	1.0	26
2	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. <i>Journal of Cardiac Failure</i> , 2022, 28, 353-366.	0.7	11
3	Understanding and tracking the impact of long COVID in the United Kingdom. <i>Nature Medicine</i> , 2022, 28, 11-15.	15.2	19
4	A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.	2.9	14
5	Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device. <i>JMIR Medical Informatics</i> , 2022, 10, e34038.	1.3	4
6	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. <i>Nature Communications</i> , 2022, 13, 624.	5.8	29
7	Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. <i>BMC Medicine</i> , 2022, 20, 63.	2.3	10
8	Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1277-1287.	2.2	15
9	Long COVID and cardiovascular disease: a learning health system approach. <i>Nature Reviews Cardiology</i> , 2022, 19, 287-288.	6.1	17
10	Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort. <i>Heart</i> , 2022, 108, 923-931.	1.2	12
11	Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 1600-1607.	1.2	15
12	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. <i>Diabetes Care</i> , 2022, 45, 1132-1140.	4.3	4
13	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. <i>Heart</i> , 2022, 108, 1200-1208.	1.2	10
14	Frameworks for Implementation, Uptake, and Use of Cardiometabolic Disease-Related Digital Health Interventions in Ethnic Minority Populations: Scoping Review. <i>JMIR Cardio</i> , 2022, 6, e37360.	0.7	4
15	The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. <i>Vaccines</i> , 2022, 10, 652.	2.1	59
16	Indirect effects of the pandemic: highlighting the need for data-driven policy and preparedness. <i>Journal of the Royal Society of Medicine</i> , 2022, 115, 249-251.	1.1	7
17	Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study. <i>BMJ</i> , The, 2022, 377, e069164.	3.0	13
18	Strategies to record and use ethnicity information in routine health data. <i>Nature Medicine</i> , 2022, 28, 1338-1342.	15.2	31

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study. <i>Global Heart</i> , 2022, 17, .	0.9	12
20	Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2138-2147.	2.2	4
21	A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease. <i>Kidney International</i> , 2022, 102, 652-660.	2.6	17
22	Valvular heart disease in the community: the unknown knowns in electronic health record coding. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 616-617.	1.8	0
23	Digital health interventions and inequalities: the case for a new paradigm. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 77-78.	1.7	11
24	Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 247-256.	1.8	54
25	Ensemble learning for poor prognosis predictions: A case study on SARS-CoV-2. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 791-800.	2.2	6
26	Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. <i>American Journal of Cardiology</i> , 2021, 141, 16-22.	0.7	3
27	The need for improved collection and coding of ethnicity in health research. <i>Journal of Public Health</i> , 2021, 43, e270-e272.	1.0	30
28	Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 75-85.	2.2	43
29	Estimating the Effect of Reduced Attendance at Emergency Departments for Suspected Cardiac Conditions on Cardiac Mortality During the COVID-19 Pandemic. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007085.	0.9	18
30	A Sustainable Community-Based Model of Noncommunicable Disease Risk Factor Surveillance (Shraddha-Jagrithi Project): Protocol for a Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e27299.	0.5	3
31	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. <i>Global Heart</i> , 2021, 16, 41.	0.9	39
32	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1599-1609.	0.8	93
33	Paying for better care?. <i>Lancet Regional Health - Europe</i> , The, 2021, 1, 100010.	3.0	0
34	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. <i>BMJ</i> , The, 2021, 372, n693.	3.0	494
35	Ethnicity, household composition and COVID-19 mortality: a national linked data study. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 182-211.	1.1	69
36	Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. <i>BMJ</i> , The, 2021, 373, n826.	3.0	98

#	ARTICLE	IF	CITATIONS
37	Performance of universal early warning scores in different patient subgroups and clinical settings: a systematic review. <i>BMJ Open</i> , 2021, 11, e045849.	0.8	12
38	Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. <i>BMC Medicine</i> , 2021, 19, 85.	2.3	33
39	Predicting endoscopic activity recovery in England after COVID-19: a national analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 381-390.	3.7	40
40	Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. <i>European Journal of Epidemiology</i> , 2021, 36, 605-617.	2.5	66
41	Understanding Race and Ethnicity in Cancer and CV Disease. <i>JACC: CardioOncology</i> , 2021, 3, 335-337.	1.7	2
42	Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 419-426.	5.5	158
43	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-218.	0.4	1
44	Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter 2 inhibitors compared with dipeptidyl peptidase 4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2207-2214.	2.2	22
45	Estimation of the economic burden of COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a model-based analysis. <i>BMJ Open</i> , 2021, 11, e049619.	0.8	20
46	World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease. <i>Lancet</i> , 2021, 398, 1467-1468.	6.3	12
47	Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 681-694.	5.5	37
48	Ethnic-minority groups in England and Wales—factors associated with the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking census and death records. <i>International Journal of Epidemiology</i> , 2021, 49, 1951-1962.	0.9	41
49	Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. <i>BMJ Open</i> , 2021, 11, e048391.	0.8	341
50	Focused action is required to protect ethnic minority populations from COVID-19 post-lockdown. <i>British Journal of General Practice</i> , 2021, 71, 37-40.	0.7	8
51	An informatics consult approach for generating clinical evidence for treatment decisions. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 281.	1.5	8
52	“What is the risk to me from COVID-19?”: Public involvement in providing mortality risk information for people with “high-risk” conditions for COVID-19 (OurRisk.CoV). <i>Clinical Medicine</i> , 2021, 21, e620-e628.	0.8	5
53	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001041.	1.2	57
54	Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. <i>Heart</i> , 2020, 106, 119-126.	1.2	76

#	ARTICLE	IF	CITATIONS
55	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. <i>European Heart Journal</i> , 2020, 41, 1636-1649.	1.0	36
56	Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. <i>Heart</i> , 2020, 106, 1890-1897.	1.2	90
57	Cardiovascular disease in homeless versus housed individuals: a systematic review of observational and interventional studies. <i>Heart</i> , 2020, 106, 1483-1488.	1.2	31
58	Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e043828.	0.8	233
59	Prevalence, incidence, and outcomes across cardiovascular diseases in homeless individuals using national linked electronic health records. <i>European Heart Journal</i> , 2020, 41, 4011-4020.	1.0	25
60	Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001–2016. <i>Scientific Reports</i> , 2020, 10, 12468.	1.6	7
61	<p>Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1095-1111.	1.5	23
62	Models for mortality require tailoring in the context of the COVID-19 pandemic – Authors' reply. <i>Lancet</i> , The, 2020, 396, 883-884.	6.3	0
63	What was right about Kerala’s response to the COVID-19 pandemic?. <i>BMJ Global Health</i> , 2020, 5, e003212.	2.0	39
64	Clinical academic research in the time of Corona: A simulation study in England and a call for action. <i>PLoS ONE</i> , 2020, 15, e0237298.	1.1	8
65	Ethnicity, heart failure and the prevention continuum: time to act. <i>Heart</i> , 2020, 106, 631-633.	1.2	2
66	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1607-1618.	2.2	118
67	Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. <i>Lancet</i> , The, 2020, 395, 1715-1725.	6.3	412
68	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. <i>The Lancet Global Health</i> , 2020, 8, e1003-e1017.	2.9	760
69	Machine learning: a long way from implementation in cardiovascular disease. <i>Heart</i> , 2020, 106, 318-320.	1.2	5
70	Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1551-1561.	1.2	55
71	Mitigating lockdown challenges in response to COVID-19 in Sub-Saharan Africa. <i>International Journal of Infectious Diseases</i> , 2020, 96, 308-310.	1.5	40
72	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	1.0	50

#	ARTICLE	IF	CITATIONS
73	Non-communicable diseases awareness and control in a rural population in an epidemiologically advanced stage of transition (Kerala): results of the epidemiology of non-communicable diseases in rural areas study. <i>International Journal of Community Medicine and Public Health</i> , 2020, 7, 2628.	0.0	2
74	Improving the digital health of the workforce in the COVID-19 context: an opportunity to future-proof medical training. <i>Future Healthcare Journal</i> , 2020, 7, 189-192.	0.6	19
75	Gender and ethnic differences in publication of BMJ letters to the editor: an observational study using machine learning. <i>BMJ Open</i> , 2020, 10, e037269.	0.8	7
76	Title is missing!. , 2020, 15, e0237298.		0
77	Title is missing!. , 2020, 15, e0237298.		0
78	Title is missing!. , 2020, 15, e0237298.		0
79	Title is missing!. , 2020, 15, e0237298.		0
80	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. <i>Europace</i> , 2019, 21, 1776-1784.	0.7	22
81	UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 1545-1559.	2.2	143
82	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	0.8	12
83	Biomagnification characteristics and health risk assessment of the neurotoxin BMAA in freshwater aquaculture products of Taihu Lake Basin, China. <i>Chemosphere</i> , 2019, 229, 332-340.	4.2	17
84	Health informatics competencies in postgraduate medical education and training in the UK: a mixed methods study. <i>BMJ Open</i> , 2019, 9, e025460.	0.8	43
85	Global health competencies in UK postgraduate medical training: a scoping review and curricular content analysis. <i>BMJ Open</i> , 2019, 9, e027577.	0.8	8
86	Validity of acute cardiovascular outcome diagnoses in European electronic health records: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e031373.	0.8	1
87	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. <i>BMC Medicine</i> , 2019, 17, 206.	2.3	12
88	There may be a role for addition of rivaroxaban to aspirin in patients with stable coronary artery disease. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 78-79.	1.7	0
89	India and the United Kingdomâ€™What big data health research can do for a country. <i>Learning Health Systems</i> , 2019, 3, e10074.	1.1	2
90	The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?. <i>Global Heart</i> , 2019, 9, 255.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Effect of propionamide on the growth of <i>Microcystis flos-aquae</i> colonies and the underlying physiological mechanisms. <i>Science of the Total Environment</i> , 2018, 630, 526-535.	3.9	22
92	Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis. <i>Global Health Action</i> , 2018, 11, 1434935.	0.7	3
93	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
94	Essential components in natriuretic peptide-guided management of heart failure: an intervention synthesis. <i>Open Heart</i> , 2018, 5, e000826.	0.9	2
95	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
96	Current computational trends in polyanionic cathode materials for Li and Na batteries. <i>Journal of Physics Condensed Matter</i> , 2018, 30, 283003.	0.7	13
97	Cardiovascular Diseases in India Compared With the United States. <i>Journal of the American College of Cardiology</i> , 2018, 72, 79-95.	1.2	76
98	Can the NHS be a learning healthcare system in the age of digital technology?. <i>BMJ Evidence-Based Medicine</i> , 2018, 23, 161-165.	1.7	6
99	Cardiotoxicity: precision medicine with imprecise definitions. <i>Open Heart</i> , 2018, 5, e000774.	0.9	33
100	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
101	Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis. <i>Global Heart</i> , 2018, 13, 27.	0.9	13
102	Personalized survival predictions via Trees of Predictors: An application to cardiac transplantation. <i>PLoS ONE</i> , 2018, 13, e0194985.	1.1	40
103	Potential for mobile health (mHealth) prevention of cardiovascular diseases in Kerala: A population-based survey. <i>Indian Heart Journal</i> , 2017, 69, 182-199.	0.2	17
104	Designing strategies to tune reduction potential of organic molecules for sustainable high capacity battery application. <i>Journal of Materials Chemistry A</i> , 2017, 5, 4430-4454.	5.2	61
105	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
106	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1-25.	1.2	2,705
107	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
108	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	13.9	5,014

#	ARTICLE	IF	CITATIONS
109	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990â€“2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 389, 1885-1906.	6.3	1,281
110	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017, 38, 1048-1055.	1.0	44
111	Health informatics in UK Medical Education: an online survey of current practice. <i>JRSM Open</i> , 2017, 8, 205427041668267.	0.2	19
112	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
113	Bridging the Global Digital Health Divide for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	5
114	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
115	Using patient data for patientsâ€™ benefit. <i>BMJ: British Medical Journal</i> , 2017, 358, j4413.	2.4	4
116	Challenges for learning health systems in the NHS. Case study: electronic health records in cardiology. <i>Future Hospital Journal</i> , 2017, 4, 193-197.	0.2	4
117	Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 837-850.	1.8	128
118	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. <i>Global Heart</i> , 2017, 12, 273.	0.9	35
119	Atrial fibrillation: the current epidemic. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 195-203.	0.2	208
120	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
121	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
122	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
123	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
124	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
125	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
126	Stable coronary disease: Cinderella must go to the ball. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 151-152.	1.8	0

#	ARTICLE	IF	CITATIONS
127	Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. <i>Open Heart</i> , 2016, 3, e000438.	0.9	36
128	Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 16.	1.1	5
129	Net clinical benefit of edoxaban versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015, 201, 693-698.	0.8	18
130	Age-specific incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined population. <i>British Journal of Surgery</i> , 2015, 102, 907-915.	0.1	98
131	Potential for the use of mHealth in the management of cardiovascular disease in Kerala: a qualitative study. <i>BMJ Open</i> , 2015, 5, e009367-e009367.	0.8	45
132	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	6.3	4,951
133	Poverty, development and cardiovascular trials: More questions than answers?. <i>Heart</i> , 2015, 101, 245-247.	1.2	2
134	Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. <i>Stroke</i> , 2015, 46, 608-609.	1.0	11
135	Below the poverty line and non-communicable diseases in Kerala: The Epidemiology of Non-communicable Diseases in Rural Areas (ENDIRA) study. <i>International Journal of Cardiology</i> , 2015, 187, 519-524.	0.8	29
136	Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS ₂ and CHA ₂ DS ₂ -VASc scores and arrhythmia recurrences. <i>Heart</i> , 2015, 101, 126-131.	1.2	26
137	Changes in health in England, with analysis by English regions and areas of deprivation, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2257-2274.	6.3	279
138	Aortic dissection in pregnancy in England: an incidence study using linked national databases. <i>BMJ Open</i> , 2015, 5, e008318.	0.8	22
139	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
140	Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events. <i>Circulation</i> , 2015, 132, 1805-1815.	1.6	148
141	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
142	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	6.3	5,847
143	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 143-150.	1.0	116
144	Purification effects of two eco-ditch systems on Chinese soft-shelled turtle greenhouse culture wastewater pollution. <i>Environmental Science and Pollution Research</i> , 2014, 21, 5610-5618.	2.7	20

#	ARTICLE	IF	CITATIONS
145	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 957-979.	6.3	609
146	Prior History of Falls and Risk of Outcomes in Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. <i>American Journal of Medicine</i> , 2014, 127, 972-978.	0.6	51
147	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	39
148	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 1005-1070.	6.3	786
149	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014, 35, 1448-1456.	1.0	190
150	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2014, 384, 766-781.	6.3	9,122
151	Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 549-556.	1.8	25
152	A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 145, 1370-1382.	0.4	66
153	Surveillance of Noncommunicable Diseases by Community Health Workers in Kerala: The Epidemiology of Noncommunicable Diseases in Rural Areas (ENDIRA) Study. <i>Global Heart</i> , 2014, 9, 409.	0.9	23
154	Abstract P362: Surveillance Of Non-Communicable Diseases By Non-Physician Health Workers In Kerala: the Epidemiology of Non-communicable Diseases in Rural Areas (ENDIRA) study. <i>Circulation</i> , 2014, 129, .	1.6	2
155	Renal Impairment and Ischemic Stroke Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2079-2087.	1.2	105
156	Is the higher risk of cardiovascular disease amongst South Asian populations linked to abnormalities of haemoglobin? A preliminary case control study. <i>Atherosclerosis</i> , 2013, 226, 198-200.	0.4	3
157	Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2013, 167, 2682-2687.	0.8	67
158	Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ CHADS		

#	ARTICLE	IF	CITATIONS
163	Editorial (Heart Failure: The Need for Global Health Perspective). <i>Current Cardiology Reviews</i> , 2013, 9, 97-98.	0.6	10
164	Heart Failure in East Asia. <i>Current Cardiology Reviews</i> , 2013, 9, 112-122.	0.6	72
165	Assessing the Risk of Bleeding in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 941-948.	2.1	68
166	What can quality improvement learn from evidence-based medicine?. <i>Journal of the Royal Society of Medicine</i> , 2012, 105, 55-59.	1.1	10
167	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012, 14, 295-301.	2.9	96
168	Association Between Family Risk of Stroke and Myocardial Infarction With Prevalent Risk Factors and Coexisting Diseases. <i>Stroke</i> , 2012, 43, 974-979.	1.0	11
169	Family history does not predict angiographic localization or severity of coronary artery disease. <i>Atherosclerosis</i> , 2012, 221, 451-457.	0.4	4
170	(13) Genetic variant of CD36 gene is not associated with Cardiovascular risk factors in South Asians. <i>Atherosclerosis</i> , 2012, 223, 531.	0.4	0
171	To the Editor" Adding renal dysfunction to CHA2DS2-VASc improves stroke prediction postcatheter ablation. <i>Heart Rhythm</i> , 2012, 9, e25.	0.3	0
172	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012, 164, 292-302.e1.	1.2	47
173	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 584-589.	1.8	289
174	Improving the diagnosis and prognosis of atrial fibrillation in stroke: quo vadis?. <i>European Journal of Neurology</i> , 2012, 19, 187-188.	1.7	1
175	Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. <i>International Journal of Clinical Practice</i> , 2012, 66, 477-492.	0.8	99
176	A review of family history of cardiovascular disease: risk factor and research tool. <i>International Journal of Clinical Practice</i> , 2012, 66, 536-543.	0.8	34
177	Tracking global funding for the prevention and control of noncommunicable diseases. <i>Bulletin of the World Health Organization</i> , 2012, 90, 479-479A.	1.5	45
178	Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1419-1431.	1.1	14
179	Avances incompletos en la estratificaci3n del riesgo de ictus en la fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 639-641.	0.6	8
180	The Improved but Unfinished Business of Stroke Risk Stratification in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 639-641.	0.4	2

#	ARTICLE	IF	CITATIONS
181	Medical student electives: potential for global health?. <i>Lancet, The</i> , 2011, 377, 555.	6.3	12
182	Bleeding risk with oral anticoagulation - new frontiers and new questions. <i>International Journal of Clinical Practice</i> , 2011, 65, 719-721.	0.8	1
183	Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. <i>BMJ: British Medical Journal</i> , 2011, 343, d4264-d4264.	2.4	9
184	Relative Familial Clustering of Cerebral Versus Coronary Ischemic Events. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 390-396.	5.1	17
185	Familial History of Stroke Is Associated With Acute Coronary Syndromes in Women. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 9-15.	5.1	32
186	Health is global â€œ what does that mean for the United Kingdom?. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 312-314.	1.1	1
187	Looking through the PRISM: New Insights for Young Patients with Atrial Fibrillation and Stroke. <i>Cerebrovascular Diseases</i> , 2011, 32, 383-384.	0.8	0
188	A New Landscape for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2011, 42, 3316-3322.	1.0	26
189	Intracerebral Hemorrhage and Warfarin. <i>Stroke</i> , 2011, 42, 2383-2384.	1.0	2
190	Medical electives: a chance for international health. <i>Journal of the Royal Society of Medicine</i> , 2010, 103, 6-8.	1.1	21
191	Associations Between Peripheral Artery Disease and Ischemic Stroke. <i>Stroke</i> , 2010, 41, 2102-2107.	1.0	81
192	The Health Impact Fund: incentives for improving access to medicines. <i>Lancet, The</i> , 2010, 375, 166-169.	6.3	72
193	Combination therapy with clopidogrel and proton-pump inhibitors. <i>Lancet, The</i> , 2010, 375, 28.	6.3	2
194	The Health Impact Fund. <i>Lancet, The</i> , 2010, 375, 1693.	6.3	3
195	The Health Impact Fund: a potential solution to inequity in global drug access. <i>Indian Journal of Medical Ethics</i> , 2010, 7, 240-3.	0.2	1
196	Sex-Specific Familial Clustering of Myocardial Infarction in Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 98-105.	5.1	17
197	The developing world in <i>The New England Journal of Medicine</i> . <i>Globalization and Health</i> , 2006, 2, 3.	2.4	29
198	Long-Term Function After Restorative Proctocolectomy. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 946-951.	0.7	33

#	ARTICLE	IF	CITATIONS
199	Differences in Cardiovascular and Renal Outcomes Between Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Among Type 2 Diabetes Patients: A Real-World, Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0